Home
overview

SMi’s conference ‘Advances in Anti-Inflammatory Therapeutics – Novel Target Candidates for Inflammatory Conditions’ will launch discussions on the latest innovations and research into new drug targets and therapeutic strategies through plenary lectures and case studies. Providing a forum where technological advances and new applications in drug discovery can be reviewed, join world leaders in the provision of the latest therapeutics and insights into the production of more efficient, safe anti-inflammatory drugs.

Hear contributions from leading industry experts, including:

  • Dr Ronald Magolda, Vice President, Medicinal Chemistry, Wyeth
  • Dr Lisa Marshall, Senior Director, Early Development & Team Leader, Compound Development, Johnson & Johnson
  • Dr Martin Braddock, Director, Discovery Bioscience, AstraZeneca
  • Dr Richard Griffiths, Director, Licensing & Development, Pfizer
  • Dr Alan Young, Associate Director, & Senior Principal Scientist, AstraZeneca
  • Dr David Rubin, Associate Director, Global Research & Development, Pfizer
  • Dr David Sterling, Chief Scientific Officer & Executive Vice President, Pharmaceutical Research & Development, Celgene
  • Dr Yajun Xu, Director, Biochemistry & Cell Signalling, Inflammation, Millennium Pharmaceuticals
  • Dr William Hipkin, Senior Principal Scientist, Schering-Plough
  • Professor Kim Rainsford, Emeritus Professor, Biomedical Sciences, Sheffield Hallam University

Key issues that will be addressed at the conference include:

  • Mechanism of action: Discover the novel action of the latest molecules and how this will influence the future anti-inflammatory drug market
  • Novel anti-inflammatory therapeutics: Discuss the latest research, development and market expansion of anti- inflammatory therapeutics
  • Case studies: Hear from leading industry experts as they discuss the latest treatment strategies for inflammatory diseases and how the industry may evolve
  • Legislative considerations: Learn how to overcome the challenges associated with licensing your drug
  • Information interchange: Interact and debate with some of the industry’s key experts and learn from their experience and expertise

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Martin Braddock

Martin Braddock, Director Discovery Bioscience, AstraZeneca

9:10 POTENTIAL ANTI-INFLAMMATORY DRUGS

Lisa Marshall

Lisa Marshall, Senior Director, Early Development & Team Leader, Compound Development, Johnson & Johnson

  • The early development process
  • Building close alliances with project teams, discovery and experimental medicine
  • The common and not so common pitfalls
  • The next steps
  • 9:50 SELECTIVE AND NON-SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

    Gordon Letts

    Gordon Letts, Senior Vice President, Research & Development & Chief Scientific Officer, NitroMed

  • Oxidative and nitrosative stress
  • Nitric oxide donors
  • In vivo and in vitro models
  • NO-cox-2’s, CINODs
  • 10:30 Morning Coffee

    10:50 MODELS OF INFLAMMATION

    Michael Seed

    Michael Seed, Senior Lecturer, William Harvey Research Institute

  • Traditional inflammation animal models
  • Links to modern mechanistic knowledge
  • Priorities: disease target or molecular target?
  • Choosing the correct model for the target
  • The way forward
  • 11:30 A NOVEL ANTI-INFLAMMATORY MECHANISM WITH BROAD THERAPEUTIC UTILITY IN CHRONIC INFLAMMATORY DISEASES

  • Novel highly selective kinase inhibitors will be discussed that suppress proinflammatory cytokines like TNF-a
  • The compounds have good oral bioavailability and may represent a novel class of oral DMARDs
  • The effects of these kinase inhibitors in various in vitro cellular assays and in vivo disease models of pain and  inflammation will be described
  • The potential of these kinase inhibitors for treatment of pain and chronic inflammatory diseases will be outlined
  • Steven  Gilman

    Steven Gilman, President & Chief Executive Officer, ActivBiotics

    Klaus Dembowsky

    Klaus Dembowsky, VP, Drug Discovery, Ingenium Pharmaceuticals AG

    12:50 Networking Lunch

    14:10 TARGETS FOR SMALL MOLECULES AND THEIR MECHANISM OF ACTION

    Wolfgang Albrecht

    Wolfgang Albrecht, Head, Drug Research, Merckle

  • The role of medicinal chemistry
  • Ecosanoids synthesis
  • Modulation of the prostaglandin synthesis by COX- and PGES- inhibitors
  • Modulation of leukotriene synthesis by 5-LOX inhibitors and FLAP-antagonists
  • Modulation of eicosanoids by phospholipase A2 inhibitors
  • Leukotriene receptor antagonists
  • New directions for anti-inflammatory drug targets and actions
  • 14:50 LATEST ADVANCES IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA)

    Yajun Xu

    Yajun Xu, Director, Millennium Pharmaceuticals

  • Reviewing the drug discovery process
  • Scientific rational and target validation
  • Lead molecule pharmacological profile
  • Biomarker discovery and development
  • Strategies in drug development
  • A look to the future in rheumatoid arthritis therapeutics
  • 15:30 Afternoon Tea

    16:00 NOVEL ANTI-INFLAMMATORY THERAPEUTIC STRATEGIES FOR TREATING CHRONIC INFLAMMATORY AND NEURODEGENERATIVE DISEASES

    Kim Rainsford

    Kim Rainsford, Emeritus Professor of Biomedical Sciences, Sheffield Hallam University

  • Traditional treatments
  • Newly evolving cellular and molecular targets for potential therapies
  • The role of cytokines, oxyradicals, ecosanoids and docosanoids in neurodegeneration
  • Regulation of nitric oxide synthases, nitric oxode/peroxynitrite generation in microvascular functions
  • Biomarker discoveries
  • The latest developments in anti-inflammatory therapeutics
  • 16:40 INFLAMMATORY PAIN

  • The pharmacology of inflammatory pain
  • Small molecule approaches – IMiDs
  • Biology of IMiDs
  • Animal models and human studies
  • Results and the implications for future research and therapeutics
  • David Stirling

    David Stirling, Chief Scientific Officer & Executive Vice President, Pharmaceutical Research & Development, Celgene

    Sai Shankar

    Sai Shankar, Research Scientist II, Celgene Corp

    17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Richard Griffiths

    Richard Griffiths, Director, Licensing & Development, Pfizer

    9:10 INFLAMMATORY DRUG LICENSING

    Richard Griffiths

    Richard Griffiths, Director, Licensing & Development, Pfizer

  • The groundwork - what preparation to do before you license?
  • Confidentiality and competition, the legal obligations
  • Inward licensing, outward licensing and evaluation opportunities
  • Minimising the financial risk
  • Important steps to take after the deal is made
  • 9:50 NOVEL SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS AS ANTI-INFLAMMATORY AGENTS

    Ronald Magolda

    Ronald Magolda, Vice President, Medicinal Chemistry, Wyeth Research

  • Chemical genomic drug discovery
  • Structure-based design
  • Potency, selectivity and efficacy profiles
  • Biological profile and anti-inflammatory properties
  • Therapeutic status and future potential
  • 10:30 Morning Coffee

    11:00 MODULATION OF T REGULATORY CELLS

    Neil Williams

    Neil Williams, Professor of Immunology, University of Bristol

  • The role of T reg cells in the immune system
  • Natural and inducible T reg in controlling inflammatory disease
  • Can we modulate the activity of T reg?
  • Pathogen derived molecules as novel immunomodulatory agents
  • 11:40 CHEMOKINE RECEPTOR ANTAGONISTS

    William Hipkin

    William Hipkin, Senior Principal Scientist, Schering Plough

  • What is the future of anti-inflammatory therapeutics targeted to chemokine receptors?
  • Novel research
  • What is the association between chemokine receptor antagonists and inflammatory disease?
  • Clinical trials data and analysis
  • The future of anti-inflammatory therapeutics?
  • 12:20 Networking Lunch

    13:30 THE USE OF IMMUNOMODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES

    Cliff Whelan

    Cliff Whelan, Director, Phlogopharm

  • An overview of immunomodulators and their therapeutic profile
  • Preclinical and clinical data supporting their use in inflammatory disease
  • Adverse event profiles and other limitations
  • Targeting the lesion – can we improve selectivity?
  • Strategies for the future – small molecular weight compounds
  • 14:50 INFLAMMATORY CONDITIONS OF THE RESPIRATORY SYSTEM

    Alan Young

    Alan Young, Associate Director & Principal Scientist, Astrazeneca

  • Presentation, pathogenesis and patient needs
  • Current therapies and hopes for the future
  • Glucocorticosteroids: room for improvements?
  • Anti-cytokine and anti-chemokine therapies: the "new kids on the block"?
  • Antisense therapies and oligonucleotides: a real option?
  • Phosphodiesterase-IV inhibitors: the same old same old?
  • Fresh research strategies and potential future therapies
  • 15:10 Afternoon Tea

    16:00 ANTI-INFLAMMATORY MEDICINES FOR CHRONIC OBSTRUCTIVE LUNG DISEASES

    David Rubin

    David Rubin, Associate Director, Global Research and Development, 200/222, Pfizer

  • Inflammation, COPD vs asthma
  • Biomarkers of inflammatory lung disease
  • Preclinical models of COPD and asthma
  • Modes of delivery
  • Targets of anti-inflammatory drugs and therapy – discussing cytokines, PDE4, etc
  • 16:40 MORE INFLAMMATORY CONDITIONS OF THE RESPIRATORY SYSTEM

    Ash Bahl

    Ash Bahl, Principal Scientist, Astrazeneca

  • Presentation and pathogenesis
  • Current therapies and the mechanism of action
  • Glucocorticoides
  • Anti-leukotrienes and 5-lioxygenase inhibitors
  • Anti-cytokine and anti-chemokine therapies
  • Antisense therapies and oligonucleotides
  • Phosphodiesterase-IV
  • Prospects for existing and new combination therapies
  • Fresh research strategies and potential future therapies
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Identification of Novel Therapeutic Targets for Anti-inflammatory Drug Development
    Workshop

    Identification of Novel Therapeutic Targets for Anti-inflammatory Drug Development

    Crowne Plaza Hotel - The City
    22nd November 2006
    London, United Kingdom

    The Modelling of Inflammation
    Workshop

    The Modelling of Inflammation

    Crowne Plaza Hotel - The City
    22nd November 2006
    London, United Kingdom

    Crowne Plaza Hotel - The City

    19 New Bridge Street
    London EC4V 6DB
    United Kingdom

    Crowne Plaza Hotel - The City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.